Seelos Therapeutics Inc
NASDAQ:SEEL
Intrinsic Value
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one SEEL stock under the Base Case scenario is 0.4 USD. Compared to the current market price of 0.3 USD, Seelos Therapeutics Inc is Undervalued by 24%.
Valuation Backtest
Seelos Therapeutics Inc
Run backtest to discover the historical profit from buying and selling SEEL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Seelos Therapeutics Inc
Current Assets | 5.4m |
Cash & Short-Term Investments | 3m |
Receivables | 763k |
Other Current Assets | 1.6m |
Non-Current Assets | 15k |
PP&E | 15k |
Current Liabilities | 38.9m |
Accounts Payable | 16.4m |
Accrued Liabilities | 2.5m |
Other Current Liabilities | 20m |
Earnings Waterfall
Seelos Therapeutics Inc
Revenue
|
2.2m
USD
|
Operating Expenses
|
-42.7m
USD
|
Operating Income
|
-40.5m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-37.9m
USD
|
Free Cash Flow Analysis
Seelos Therapeutics Inc
SEEL Profitability Score
Profitability Due Diligence
Seelos Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Seelos Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
SEEL Solvency Score
Solvency Due Diligence
Seelos Therapeutics Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
Seelos Therapeutics Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SEEL Price Targets Summary
Seelos Therapeutics Inc
Ownership
SEEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SEEL Price
Seelos Therapeutics Inc
Average Annual Return | -22.08% |
Standard Deviation of Annual Returns | 40.31% |
Max Drawdown | -100% |
Market Capitalization | 4.1m USD |
Shares Outstanding | 13 680 600 |
Percentage of Shares Shorted | 5.11% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
Contact
IPO
Employees
Officers
The intrinsic value of one SEEL stock under the Base Case scenario is 0.4 USD.
Compared to the current market price of 0.3 USD, Seelos Therapeutics Inc is Undervalued by 24%.